<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xml:lang="en" article-type="editorial" xmlns:xlink="http://www.w3.org/1999/xlink">
<?release-delay 0|0?>
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">IJO</journal-id>
<journal-title-group>
<journal-title>International Journal of Oncology</journal-title>
</journal-title-group>
<issn pub-type="ppub">1019-6439</issn>
<issn pub-type="epub">1791-2423</issn>
<publisher>
<publisher-name>D.A. Spandidos</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">IJO-0-0-05216</article-id>
<article-id pub-id-type="doi">10.3892/ijo.2021.5216</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Editorial</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The International Journal of Oncology: 30 years of progress (1992-2021)</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Spandidos</surname><given-names>Demetrios A.</given-names></name>
<xref rid="af1-ijo-0-0-05216" ref-type="aff"/>
</contrib>
</contrib-group>
<pub-date pub-type="ppub">
<month>07</month>
<year>2021</year></pub-date>
<pub-date pub-type="epub">
<day>07</day>
<month>05</month>
<year>2021</year></pub-date>
<volume>59</volume>
<issue>1</issue>
<elocation-id>36</elocation-id>
<history>
<date date-type="received">
<day>07</day>
<month>05</month>
<year>2021</year>
</date>
<date date-type="accepted">
<day>07</day>
<month>05</month>
<year>2021</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright: &#x00A9; Spandidos et al.</copyright-statement>
<copyright-year>2021</copyright-year>
</permissions>
</article-meta>
</front>
<body>
<sec>
<title/>
<p>We are hereby very pleased to announce that the International Journal of Oncology is now celebrating its 30th year of publication since the inaugural issue in 1992. During this time span of three decades, the journal has had the pleasure of publishing a variety of research articles and reviews submitted by authors from around the world, thus bringing to light new insight into the field of oncology. The International Journal of Oncology has always aimed to publish high quality research on oncology from a diversity of international contributors. This diversity is depicted in Table I below, which presents the list of countries from which the articles have originated over the years. We would also like to take this opportunity to thank all the authors and reviewers who have contributed to the success of the journal over the years, and with their support, we look forward to an even brighter future.</p>
</sec>
</body>
<floats-group>
<fig id="f1-etm-0-0-aaaa" position="float">
<label/>
<caption><p>&#x00A0;</p></caption>
<graphic xlink:href="ijo-59-01-05216-g00.tif" />
</fig>
<table-wrap id="tI-ijo-0-0-05216" position="float">
<label>Table I</label>
<caption><p>International Journal of Oncology (1992-June 2021).</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="middle">Country</th>
<th align="center" valign="middle">No. of articles (% total)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="middle">1. USA</td>
<td align="center" valign="middle">2,514 (22.7)</td>
</tr>
<tr>
<td align="left" valign="middle">2. Japan</td>
<td align="center" valign="middle">2,421 (21.9)</td>
</tr>
<tr>
<td align="left" valign="middle">3. P.R. China</td>
<td align="center" valign="middle">1,061 (9.6)</td>
</tr>
<tr>
<td align="left" valign="middle">4. Germany</td>
<td align="center" valign="middle">854 (7.7)</td>
</tr>
<tr>
<td align="left" valign="middle">5. Italy</td>
<td align="center" valign="middle">669 (6.0)</td>
</tr>
<tr>
<td align="left" valign="middle">6. South Korea</td>
<td align="center" valign="middle">533 (4.8)</td>
</tr>
<tr>
<td align="left" valign="middle">7. UK</td>
<td align="center" valign="middle">437 (3.9)</td>
</tr>
<tr>
<td align="left" valign="middle">8. France</td>
<td align="center" valign="middle">317 (2.9)</td>
</tr>
<tr>
<td align="left" valign="middle">9. Sweden</td>
<td align="center" valign="middle">288  (2.6)</td>
</tr>
<tr>
<td align="left" valign="middle">10. Canada</td>
<td align="center" valign="middle">202 (1.8)</td>
</tr>
<tr>
<td align="left" valign="middle">11. Spain</td>
<td align="center" valign="middle">123</td>
</tr>
<tr>
<td align="left" valign="middle">12. Belgium</td>
<td align="center" valign="middle">110</td>
</tr>
<tr>
<td align="left" valign="middle">13. Taiwan R.O.C</td>
<td align="center" valign="middle">109</td>
</tr>
<tr>
<td align="left" valign="middle">14. Austria</td>
<td align="center" valign="middle">95</td>
</tr>
<tr>
<td align="left" valign="middle">15. Czech Republic</td>
<td align="center" valign="middle">94</td>
</tr>
<tr>
<td align="left" valign="middle">16. Switzerland</td>
<td align="center" valign="middle">91</td>
</tr>
<tr>
<td align="left" valign="middle">17. Greece</td>
<td align="center" valign="middle">85</td>
</tr>
<tr>
<td align="left" valign="middle">18. The Netherlands</td>
<td align="center" valign="middle">85</td>
</tr>
<tr>
<td align="left" valign="middle">19. Poland</td>
<td align="center" valign="middle">79</td>
</tr>
<tr>
<td align="left" valign="middle">20. Singapore</td>
<td align="center" valign="middle">74</td>
</tr>
<tr>
<td align="left" valign="middle">21. Israel</td>
<td align="center" valign="middle">72</td>
</tr>
<tr>
<td align="left" valign="middle">22. Norway</td>
<td align="center" valign="middle">71</td>
</tr>
<tr>
<td align="left" valign="middle">23. Australia</td>
<td align="center" valign="middle">68</td>
</tr>
<tr>
<td align="left" valign="middle">24. Hong Kong</td>
<td align="center" valign="middle">56</td>
</tr>
<tr>
<td align="left" valign="middle">25. Denmark</td>
<td align="center" valign="middle">52</td>
</tr>
<tr>
<td align="left" valign="middle">26. India</td>
<td align="center" valign="middle">43</td>
</tr>
<tr>
<td align="left" valign="middle">27. Brazil</td>
<td align="center" valign="middle">40</td>
</tr>
<tr>
<td align="left" valign="middle">28. Finland</td>
<td align="center" valign="middle">34</td>
</tr>
<tr>
<td align="left" valign="middle">29. Argentina</td>
<td align="center" valign="middle">28</td>
</tr>
<tr>
<td align="left" valign="middle">30. Chile</td>
<td align="center" valign="middle">26</td>
</tr>
<tr>
<td align="left" valign="middle">31. Mexico</td>
<td align="center" valign="middle">23</td>
</tr>
<tr>
<td align="left" valign="middle">32. Egypt</td>
<td align="center" valign="middle">22</td>
</tr>
<tr>
<td align="left" valign="middle">33. Hungary</td>
<td align="center" valign="middle">22</td>
</tr>
<tr>
<td align="left" valign="middle">34. Thailand</td>
<td align="center" valign="middle">22</td>
</tr>
<tr>
<td align="left" valign="middle">35. Saudi Arabia</td>
<td align="center" valign="middle">20</td>
</tr>
<tr>
<td align="left" valign="middle">36. Ireland</td>
<td align="center" valign="middle">19</td>
</tr>
<tr>
<td align="left" valign="middle">37. South Africa</td>
<td align="center" valign="middle">19</td>
</tr>
<tr>
<td align="left" valign="middle">38. Russia</td>
<td align="center" valign="middle">17</td>
</tr>
<tr>
<td align="left" valign="middle">39. Slovak Republic</td>
<td align="center" valign="middle">15</td>
</tr>
<tr>
<td align="left" valign="middle">40. Lebanon</td>
<td align="center" valign="middle">11</td>
</tr>
<tr>
<td align="left" valign="middle">41. Croatia</td>
<td align="center" valign="middle">9</td>
</tr>
<tr>
<td align="left" valign="middle">42. Turkey</td>
<td align="center" valign="middle">9</td>
</tr>
<tr>
<td align="left" valign="middle">43. Kuwait</td>
<td align="center" valign="middle">8</td>
</tr>
<tr>
<td align="left" valign="middle">44. Malaysia</td>
<td align="center" valign="middle">8</td>
</tr>
<tr>
<td align="left" valign="middle">45. Portugal </td>
<td align="center" valign="middle">8</td>
</tr>
<tr>
<td align="left" valign="middle">46. Indonesia</td>
<td align="center" valign="middle">7</td>
</tr>
<tr>
<td align="left" valign="middle">47. Luxembourg</td>
<td align="center" valign="middle">6</td>
</tr>
<tr>
<td align="left" valign="middle">48. Tunisia</td>
<td align="center" valign="middle">6</td>
</tr>
<tr>
<td align="left" valign="middle">49. Estonia</td>
<td align="center" valign="middle">5</td>
</tr>
<tr>
<td align="left" valign="middle">50. Guatemala</td>
<td align="center" valign="middle">5</td>
</tr>
<tr>
<td align="left" valign="middle">51. Iceland</td>
<td align="center" valign="middle">5</td>
</tr>
<tr>
<td align="left" valign="middle">52. New Zealand</td>
<td align="center" valign="middle">5</td>
</tr>
<tr>
<td align="left" valign="middle">53. Romania</td>
<td align="center" valign="middle">5</td>
</tr>
<tr>
<td align="left" valign="middle">54. Slovenia</td>
<td align="center" valign="middle">5</td>
</tr>
<tr>
<td align="left" valign="middle">55. United Arab Emirates</td>
<td align="center" valign="middle">5</td>
</tr>
<tr>
<td align="left" valign="middle">56. Vietnam</td>
<td align="center" valign="middle">5</td>
</tr>
<tr>
<td align="left" valign="middle">57. Uruguay</td>
<td align="center" valign="middle">4</td>
</tr>
<tr>
<td align="left" valign="middle">58. Pakistan</td>
<td align="center" valign="middle">3</td>
</tr>
<tr>
<td align="left" valign="middle">59. Philippines</td>
<td align="center" valign="middle">3</td>
</tr>
<tr>
<td align="left" valign="middle">60. Cuba</td>
<td align="center" valign="middle">2</td>
</tr>
<tr>
<td align="left" valign="middle">61. Cyprus</td>
<td align="center" valign="middle">2</td>
</tr>
<tr>
<td align="left" valign="middle">62. Ethiopia</td>
<td align="center" valign="middle">2</td>
</tr>
<tr>
<td align="left" valign="middle">63. Guadeloupe</td>
<td align="center" valign="middle">2</td>
</tr>
<tr>
<td align="left" valign="middle">64. Iran</td>
<td align="center" valign="middle">2</td>
</tr>
<tr>
<td align="left" valign="middle">65. Lithuania</td>
<td align="center" valign="middle">2</td>
</tr>
<tr>
<td align="left" valign="middle">66. Qatar</td>
<td align="center" valign="middle">2</td>
</tr>
<tr>
<td align="left" valign="middle">67. Serbia</td>
<td align="center" valign="middle">2</td>
</tr>
<tr>
<td align="left" valign="middle">68. Syria</td>
<td align="center" valign="middle">2</td>
</tr>
<tr>
<td align="left" valign="middle">69. Tanzania</td>
<td align="center" valign="middle">2</td>
</tr>
<tr>
<td align="left" valign="middle">70. Ukraine</td>
<td align="center" valign="middle">2</td>
</tr>
<tr>
<td align="left" valign="middle">71. Venezouela</td>
<td align="center" valign="middle">2</td>
</tr>
<tr>
<td align="left" valign="middle">72. Armenia</td>
<td align="center" valign="middle">1</td>
</tr>
<tr>
<td align="left" valign="middle">73. Belarus</td>
<td align="center" valign="middle">1</td>
</tr>
<tr>
<td align="left" valign="middle">74. Burkina Faso</td>
<td align="center" valign="middle">1</td>
</tr>
<tr>
<td align="left" valign="middle">75. Colombia</td>
<td align="center" valign="middle">1</td>
</tr>
<tr>
<td align="left" valign="middle">76. Honduras</td>
<td align="center" valign="middle">1</td>
</tr>
<tr>
<td align="left" valign="middle">77. Iraq</td>
<td align="center" valign="middle">1</td>
</tr>
<tr>
<td align="left" valign="middle">78. Libya</td>
<td align="center" valign="middle">1</td>
</tr>
<tr>
<td align="left" valign="middle">79. Martinique</td>
<td align="center" valign="middle">1</td>
</tr>
<tr>
<td align="left" valign="middle">80. Morocco</td>
<td align="center" valign="middle">1</td>
</tr>
<tr>
<td align="left" valign="middle">81. Republic of Cameroon</td>
<td align="center" valign="middle">1</td>
</tr>
<tr>
<td align="left" valign="middle">82. Tajikistan</td>
<td align="center" valign="middle">1</td>
</tr>
<tr>
<td align="left" valign="middle">83. Yemen</td>
<td align="center" valign="middle">1</td>
</tr>
<tr>
<td align="left" valign="middle">Total<sup><xref rid="tfn1-ijo-0-0-05216" ref-type="table-fn">a</xref></sup></td>
<td align="center" valign="middle">11,070</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="tfn1-ijo-0-0-05216"><p><sup>a</sup>Some articles were published jointly with scientists from more than one country. The actual total number of articles is 9,331.</p></fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="tII-ijo-0-0-05216" position="float">
<label/>
<caption><p>The most frequently cited publications are presented.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="center" valign="middle">&#x00A0;</th>
<th align="center" valign="middle">PUBLICATIONS</th>
<th align="center" valign="middle">&#x00A0;</th>
<th align="center" valign="middle">CITATIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="middle">1.</td>
<td align="left" valign="middle">THE ANTI-MALARIAL ARTESUNATE IS ALSO ACTIVE AGAINST CANCER</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">508</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">By: EFFERTH T, DUNSTAN H, SAUERBREY A, <italic>et al</italic></td>
<td align="left" valign="middle">Int J Oncol 18: 767-773, 2001</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">2.</td>
<td align="left" valign="middle">A NEW FLUOROMETRIC ASSAY FOR CYTOTOXICITY MEASUREMENTS IN VITRO</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">502</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">By: PAGE B, PAGE M, NOEL C</td>
<td align="left" valign="middle">Int J Oncol 3: 473-476, 1993</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">3.</td>
<td align="left" valign="middle">TEA IN CHEMOPREVENTION OF CANCER: EPIDEMIOLOGIC AND EXPERIMENTAL STUDIES (REVIEW)</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">412</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">By: KATIYAR SK, MUKHTAR H</td>
<td align="left" valign="middle">Int J Oncol 8: 221-238, 1996</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">4.</td>
<td align="left" valign="middle">HUMAN FOX GENE FAMILY (REVIEW)</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">402</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">By: KATOH M, KATOH M</td>
<td align="left" valign="middle">Int J Oncol 25: 1495-1500, 2004</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">5.</td>
<td align="left" valign="middle">APIGENIN AND CANCER CHEMOPREVENTION: PROGRESS, POTENTIAL AND PROMISE (REVIEW)</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">380</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">By: PATEL D, SHUKLA S, GUPTA S</td>
<td align="left" valign="middle">Int J Oncol 30: 233-245, 2007</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">6.</td>
<td align="left" valign="middle">REGULATION OF CELL CYCLE PROGRESSION AND APOPTOSIS BY THE Ras/Raf/MEK/ERK PATHWAY (REVIEW)</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">341</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">By: CHANG FM, STEELMAN LS, SHELTON JG, <italic>et al</italic></td>
<td align="left" valign="middle">Int J Oncol 22: 469-480, 2003</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">7.</td>
<td align="left" valign="middle">CHEMORESISTANCE TO PACLITAXEL INDUCES EPITHELIAL-MESENCHYMAL TRANSITION AND ENHANCES METASTATIC POTENTIAL FOR EPITHELIAL OVARIAN CARCINOMA CELLS</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">332</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">By: KAJIYAMA H, SHIBATA K, TERAUCHI M, <italic>et al</italic></td>
<td align="left" valign="middle">Int J Oncol 31: 277-283, 2007</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">8.</td>
<td align="left" valign="middle">OVER- AND UNDER-EXPRESSED microRNAs IN HUMAN COLORECTAL CANCER</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">306</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">By: MOTOYAMA K, INOUE H, TAKATSUNO Y, <italic>et al</italic> </td>
<td align="left" valign="middle">Int J Oncol 34: 1069-1075, 2009</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">9.</td>
<td align="left" valign="middle">CANCER CHEMOPREVENTION BY RESVERATROL: IN VITRO AND IN VIVO STUDIES AND THE UNDERLYING MECHANISMS (REVIEW)</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">284</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">By: AZIZ MH, KUMAR R, AHMAD N</td>
<td align="left" valign="middle">Int J Oncol 23: 17-28, 2003</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">10.</td>
<td align="left" valign="middle">INDUCTION OF CELL CYCLE ARREST AND APOPTOSIS IN HUMAN BREAST CANCER CELLS BY QUERCETIN</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">284</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">By: CHOI JA, KIM JY, LEE JY, <italic>et al</italic></td>
<td align="left" valign="middle">Int J Oncol 19: 837-844, 2001</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">11.</td>
<td align="left" valign="middle">ANTIPROLIFERATIVE EFFECT OF SYNTHETIC RESVERATROL ON HUMAN BREAST EPITHELIAL CELLS</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">279</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">By: MGBONYEBI OP, RUSSO J, RUSSO IH</td>
<td align="left" valign="middle">Int J Oncol 12: 865-869, 1998</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">12.</td>
<td align="left" valign="middle">MALAT-1: A LONG NON-CODING RNA AND ITS IMPORTANT 3’ END FUNCTIONAL MOTIF IN COLORECTAL CANCER METASTASIS</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">277</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">By: XU C, YANG M, TIAN J, <italic>et al</italic></td>
<td align="left" valign="middle">Int J Oncol 39: 169-175, 2011</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">13.</td>
<td align="left" valign="middle">CELL DEATH: APOPTOSIS VERSUS NECROSIS (REVIEW)</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">267</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">By: KANDUC D, MITTELMAN A, SERPICO R, <italic>et al</italic></td>
<td align="left" valign="middle">Int J Oncol 21: 165-170, 2002</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">14.</td>
<td align="left" valign="middle">DNA STRAND BREAKS OCCURRING DURING APOPTOSIS - THEIR EARLY IN SITU DETECTION BY THE TERMINAL DEOXYNUCLEOTIDYL TRANSFERASE AND NICK TRANSLATION ASSAYS AND PREVENTION BY SERINE PROTEASE INHIBITORS</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">263</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">By: GORCZYCA W, BRUNO S, DARZYNKIEWICZ RJ, <italic>et al</italic></td>
<td align="left" valign="middle">Int J Oncol 1: 639-648, 1992</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">15.</td>
<td align="left" valign="middle">FLAVOPIRIDOL (L86 8275; NSC 649890), A NEW KINASE INHIBITOR FOR TUMOR THERAPY</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">254</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">By: SEDLACEK HH, CZECH J, NAIK R, <italic>et al</italic></td>
<td align="left" valign="middle">Int J Oncol 9: 1143-1168, 1996</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">16.</td>
<td align="left" valign="middle">EXPRESSION AND EPITHELIAL CELL ADHESION MOLECULE IN CARCINOMA CELLS PRESENT IN BLOOD AND PRIMARY AND METASTATIC TUMORS</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">252</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">By: RAO CG, CHIANESE D, DOYLE GV, <italic>et al</italic></td>
<td align="left" valign="middle">Int J Oncol 27: 49-57, 2005</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">17.</td>
<td align="left" valign="middle">TUMOR ASSOCIATED MACROPHAGES IN HUMAN PROSTATE CANCER: RELATION TO CLINICOPATHOLOGICAL VARIABLES AND SURVIVAL</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">252</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">By: LISSBRANT IF, STATTIN P, WIKSTROM P, <italic>et al</italic></td>
<td align="left" valign="middle">Int J Oncol 17: 445-451, 2000</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">18.</td>
<td align="left" valign="middle">THE HMGA PROTEINS: A MYRIAD OF FUNCTIONS (REVIEW)</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">244</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">By: CLEYNEN I, VAN DE VEN WJM</td>
<td align="left" valign="middle">Int J Oncol 32: 289-305, 2008</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">19.</td>
<td align="left" valign="middle">CIRCULATING microRNAs: NEW BIOMARKERS IN DIAGNOSIS, PROGNOSIS AND TREATMENT OF CANCER (REVIEW)</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">240</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">By: ALLEGRA A, ALONCI A, CAMPO S, <italic>et al</italic></td>
<td align="left" valign="middle">Int J Oncol 41: 1897-1912, 2012</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">20.</td>
<td align="left" valign="middle">RADIATION-INDUCED AUTOPHAGY IS ASSOCIATED WITH LC3 AND ITS INHIBITION SENSITIZES MALIGNANT GLIOMA CELLS</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">237</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">By: ITO H, DAIDO S, KANZAWA T, <italic>et al</italic></td>
<td align="left" valign="middle">Int J Oncol 26: 1401-1410, 2005</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn><p>Data obtained from the Web of Science Clarivate Analytics 06/05/2021.</p></fn>
</table-wrap-foot>
</table-wrap>
</floats-group>
</article>
